(Q37683766)

22 August 2017

1 reference

title

Dasatinib in solid tumors (English)

1 reference

22 August 2017

main subject

dasatinib monohydrate

1 reference

1 reference

Lori C Kim

1

1 reference

22 August 2017

Uwe Rix

series ordinal

2

1 reference

22 August 2017

Eric B Haura

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

415-425

1 reference

22 August 2017

cites work

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Src kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Role of Src expression and activation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Targeting Src in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Src as a potential therapeutic target in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Target profiling of small molecules by chemical proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

c-Src and cooperating partners in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Targeting Src signaling in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003592097

10.1517/13543781003592097

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference